Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

161. Treatment of superficial œsophageal cancer by endoscopic submucosal dissection (ESD)

Treatment of superficial œsophageal cancer by endoscopic submucosal dissection (ESD) Treatment of superficial œsophageal cancer by endoscopic submucosal dissection (ESD) - INAHTA Brief

2019 Haute Autorite de sante

162. Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD)

Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD) Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD) - INAHTA Brief

2019 Haute Autorite de sante

163. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

2019 Haute Autorite de sante

164. Treatment of superficial colon cancer by endoscopic submucosal dissection

Treatment of superficial colon cancer by endoscopic submucosal dissection Treatment of superficial colon cancer by endoscopic submucosal dissection - INAHTA Brief

2019 Haute Autorite de sante

165. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer INAHTA Brief Issue 2019 Title Clinical utility of genomic signatures in early-stage breast cancer Agency HAS, French National Authority for Health (Haute Autorité de santé) 5 avenue du Stade de France – F 93218 La Plaine Cedex, France Tel: +33 (0)1 55 93 70 00, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number 978-2-11-152376-0, link to full report https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite (...) - clinique-des-signatures-genomiques-dans-le-cancer-du-sein-de-stade-precoce-rapport-d-evaluation?xtmc=&xtcr=1 Aim Evaluate the clinical utility of four genomic signatures (GS) 1 , currently and temporarily funded on a conditional basis as part of a specific funding program for research and innovation (known in France as RIHN). The aim of the evaluation is to assess funding eligibility for the traditional reimbursement schemes offered by the National Health Insurance Fund. The four GS are decision-making

2019 Haute Autorite de sante

166. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer Update

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer Update Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01461 Journal of Clinical Oncology - published online before print August 5, 2019 PMID: Venous Thromboembolism (...) Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update , MB ChB 1 x Nigel S. Key ; , MD 2 x Alok A. Khorana ; , MD 3 x Nicole M. Kuderer ; , ScD 4 x Kari Bohlke ; , MD, MSc 5 x Agnes Y.Y. Lee ; , MD, PhD 6 x Juan I. Arcelus ; , MD, MS 7 x Sandra L. Wong ; , DO 8 x Edward P. Balaban ; , MD, MS 9 x Christopher R. Flowers ; , MD 10 x Charles W. Francis ; 11 x Leigh E. Gates ; , MBBS, PhD 12 x Ajay K. Kakkar ; , MD, MSc 13 x Mark N. Levine ; , MD 14 x Howard A. Liebman

2019 American Society of Clinical Oncology Guidelines

167. Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial

Resection of Cavity Shave Margins in Stage 0-III Breast Cancer Patients Undergoing Breast Conserving Surgery: A Prospective Multicenter Randomized Controlled Trial Single-center studies have demonstrated that resection of cavity shave margins (CSM) halves the rate of positive margins and re-excision in breast cancer patients undergoing partial mastectomy (PM). We sought to determine if these findings were externally generalizable across practice settings.In this multicenter randomized (...) controlled trial occurring in 9 centers across the United States, stage 0-III breast cancer patients undergoing PM were randomly assigned to either have resection of CSM ("shave" group) or not ("no shave" group). Randomization occurred intraoperatively, after the surgeon had completed their standard PM. Primary outcome measures were positive margin and re-excision rates.Between July 28, 2016 and April 13, 2018, 400 patients were enrolled in this trial. Four patients (2 in each arm) did not meet inclusion

2019 EvidenceUpdates

168. Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes

Total Neoadjuvant Therapy in Rectal Cancer: A Systematic Review and Meta-analysis of Treatment Outcomes The addition of induction chemotherapy to concomitant neoadjuvant chemoradiation in locally advanced rectal cancer could increase pathological downstaging and act on occult micrometastatic disease, leading ultimately to a better outcome. A systematic review was carried out of the existing literature on the treatment outcomes of total neoadjuvant therapy (TNT) on locally advanced rectal cancer

2019 EvidenceUpdates

169. Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT

Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT Individualising breast cancer treatment to improve survival and minimise complications in older women: a research programme including the PLACE RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page (...) from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This research programme on individualising breast cancer treatment for older women included the PLACE trial for arm lymphoedema, which closed early, but has not reported yet. {{author}} {{($index , , , , , , , & . Nigel Bundred 1, 2, * , Chris Todd 3 , Julie Morris 1, 2, 4 , Vaughan Keeley 5 , Arnie Purushotham 6

2019 NIHR HTA programme

170. Rucaparib (Rubraca) - as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

Rucaparib (Rubraca) - as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer Published 12 August 2019 www.scottishmedicines.org.uk Statement of advice SMC2221 rucaparib 200mg, 250mg and 300mg film-coated tablets (Rubraca®) Clovis Oncology UK Ltd 5 July 2019 Advice context: No part of this advice may be used without the whole of the advice (...) peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

2019 Scottish Medicines Consortium

171. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing Final Recommendation Statement: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic (...) Testing Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with BRCA1/2 gene mutation The USPSTF recommends that primary care clinicians assess women

2019 U.S. Preventive Services Task Force

172. Muscle-invasive bladder cancer

Muscle-invasive bladder cancer CUAJ – CUA Guideline Kulkarni et al Guideline: MIBC Canadian Urological Association guideline: Muscle-invasive bladder cancer Girish S. Kulkarni 1 ; Peter C. Black 2 ; Srikala S. Sridhar 3 ; Anil Kapoor 4 ; Alexandre R. Zlotta 1 ; Bobby Shayegan 4 ; Ricardo Rendon 5 ; Peter Chung 6 ; Theodorus van der Kwast 7 ; Nimira Alimohamed 8 ; Yves Fradet 9 ; Wassim Kassouf 10 1 Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer (...) Centre, University Health Network, University of Toronto, Toronto, ON, Canada; 2 Department of Urologic Sciences, University of British Columbia,Vancouver, BC, Canada; 3 Division of Hematology and Medical Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada; 4 Section of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada; 5 Department of Urology, Dalhousie University, Halifax, NS, Canada; 6 Radiation Medicine Program

2019 Canadian Urological Association

173. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer

Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO (...) .19.00948 Journal of Clinical Oncology - published online before print June 17, 2019 PMID: Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline , MD, PhD 1 x N. Lynn Henry ; , PhD 2 x Mark R. Somerfield ; , MD 3 x Vandana G. Abramson ; , MD 2 x Nofisat Ismaila ; , MD 4 x Kimberly H. Allison ; , MD 5 x Carey K. Anders ; , MS, MFA 6 x Diana T. Chingos ; , MD 7 x Andrea

2019 American Society of Clinical Oncology Guidelines

174. Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial

Perioperative Pregabalin and Intraoperative Lidocaine Infusion to Reduce Persistent Neuropathic Pain After Breast Cancer Surgery: A Multicenter, Factorial, Randomized, Controlled Pilot Trial Persistent postsurgical pain is defined as pain localized to the area of surgery of a duration of ≥2 months and is, unfortunately, a common complication after breast cancer surgery. Although there is insufficient evidence to support any preventative strategy, prior literature suggests the possible efficacy (...) of intravenous lidocaine and perioperative pregabalin in preventing persistent pain after surgery. To determine feasibility of conducting a larger definitive trial, we conducted a multicenter 2 × 2 factorial, randomized, placebo-controlled pilot trial of 100 female patients undergoing breast cancer surgery. Patients were randomized to receive an intraoperative lidocaine infusion (1.5 mg/kg bolus followed by 2 mg/kg/h) or placebo and perioperative pregabalin (300 mg preoperatively, 75 mg twice daily for 9

2019 EvidenceUpdates

175. Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer

Meta-analysis of the effect of extending the interval after long-course chemoradiotherapy before surgery in locally advanced rectal cancer The current standard of care in locally advanced rectal cancer (LARC) is neoadjuvant long-course chemoradiotherapy (nCRT) followed by total mesorectal excision (TME). Surgery is conventionally performed approximately 6-8 weeks after nCRT. This study aimed to determine the effect on outcomes of extending this interval.A systematic search was performed

2019 EvidenceUpdates

176. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer Ribociclib with fulv Ribociclib with fulvestr estrant for treating ant for treating hormone receptor-positiv hormone receptor-positive, e, HER2-negativ HER2-negative, advanced breast cancer e, advanced breast cancer T echnology appraisal guidance Published: 14 August 2019 www.nice.org.uk/guidance/ta593 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk (...) to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593) © NICE 2019. All rights

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

177. Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer

Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer T T r ransurethr ansurethral laser ablation for recurrent non- al laser ablation for recurrent non- muscle-in muscle-invasiv vasive bladder cancer e bladder cancer Interventional procedures guidance Published: 24 July 2019 www.nice.org.uk/guidance/ipg656 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) ablation for recurrent non- muscle-invasive bladder cancer shows that there are no major safety concerns. However, current evidence on its efficacy is limited in quality and quantity. Therefore, this procedure should only be used with special arrangements for © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 5clinical governance, consent, and audit or research. 1.2 Clinicians wishing to do transurethral laser

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

178. LysaKare (arginine / lysine) - to protect the kidneys from radiation damage during cancer treatment with radioactive lutetium (177Lu) oxodotreotide.

LysaKare (arginine / lysine) - to protect the kidneys from radiation damage during cancer treatment with radioactive lutetium (177Lu) oxodotreotide. Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source (...) is acknowledged. EMA/378037/2019 EMEA/H/C/004541 LysaKare (arginine / lysine) An overview of LysaKare and why it is authorised in the EU What is LysaKare and what is it used for? LysaKare is a medicine used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium ( 177 Lu) oxodotreotide. LysaKare is for use in adults and contains the active substances arginine and lysine. How is LysaKare used? LysaKare is given by infusion (drip) in to a vein over 4

2019 European Medicines Agency - EPARs

179. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer Dacomitinib for untreated EGFR Dacomitinib for untreated EGFR mutation-positiv mutation-positive non-small-cell lung e non-small-cell lung cancer cancer T echnology appraisal guidance Published: 14 August 2019 www.nice.org.uk/guidance/ta595 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

180. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer L Low-energy contact X ow-energy contact X-r -ra ay br y brach achyther ytherap apy (the y (the P Papillon technique apillon technique) for locally advanced rectal ) for locally advanced rectal cancer cancer Interventional procedures guidance Published: 14 August 2019 www.nice.org.uk/guidance/ipg659 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived (...) . 1 1 Recommendations Recommendations 1.1 Current evidence on the safety and efficacy of low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer is inadequate in quantity and quality. Therefore, this procedure should only be © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 4used in the context of research. 1.2 Further research should include randomised controlled

2019 National Institute for Health and Clinical Excellence - Interventional Procedures